Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurowave launches neuromodulation device for postoperative nausea

This article was originally published in Clinica

Executive Summary

Neurowave Medical Technologies has launched Reletex, a transdermal neuromodulation device designed to treat postoperative nausea, in the US. The device is worn on the wrist and generates electrical pulses that stimulate the centre of nausea control in the brain, Neurowave claims. This produces anti-nausea signals that travel from the vagus nerve to the digestive system. Reletex provides “almost immediate” relief to patients, the Chicago, Illinois-based firm said, adding that almost every patient undergoing surgery suffers from nausea. The device is cleared by the US FDA as an adjunct to anti-emetic drugs for postoperative nausea. It could reduce the need for these drugs, thereby minimising side-effects and drug interactions, Neurowave believes. The firm also markets devices for other types of nausea, including morning sickness and motion sickness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel